erythromycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	1048	114-07-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: erythromycin gluceptate erythromycin lactobionate erythromycin stearate erythromycin Erythromycin A erythrocin erythromycin phosphate erythromycin thiocyanate	A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Molecular weight: 733.94 Formula: C37H67NO13 CLOGP: 1.63 LIPINSKI: 2 HAC: 14 HDO: 5 TPSA: 193.91 ALOGS: -3.20 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

erythromycin gluceptate
erythromycin lactobionate
erythromycin stearate
erythromycin
Erythromycin A
erythrocin
erythromycin phosphate
erythromycin thiocyanate

A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.

Molecular weight: 733.94
Formula: C37H67NO13
CLOGP: 1.63
LIPINSKI: 2
HAC: 14
HDO: 5
TPSA: 193.91
ALOGS: -3.20
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	g	O
2	g	O
1	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	90.88 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	35 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.95 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 24, 1964	FDA	ARBOR PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	4895.11	12.29	2234	18180	248776	50335934
International normalised ratio fluctuation	198.30	12.29	61	20353	2129	50582581
Bloody discharge	129.14	12.29	38	20376	1136	50583574
Lyme disease	93.14	12.29	36	20378	2507	50582203
Seronegative arthritis	89.34	12.29	33	20381	2028	50582682
Exposure during pregnancy	66.33	12.29	149	20265	120866	50463844
Necrosis ischaemic	62.89	12.29	20	20394	779	50583931
Anaphylactic reaction	60.93	12.29	91	20323	53964	50530746
Wheezing	51.60	12.29	91	20323	61956	50522754
Dislocation of vertebra	51.25	12.29	25	20389	3062	50581648
Faecal volume decreased	50.77	12.29	12	20402	148	50584562
Beta haemolytic streptococcal infection	50.06	12.29	21	20393	1809	50582901
Pneumonia streptococcal	48.96	12.29	20	20394	1611	50583099
Drug interaction	48.01	12.29	183	20231	199438	50385272
Amniotic cavity infection	44.51	12.29	17	20397	1146	50583564
Vomiting	42.95	12.29	325	20089	460433	50124277
Rash	39.87	12.29	307	20107	437164	50147546
Pneumococcal infection	39.52	12.29	12	20402	400	50584310
Ototoxicity	37.91	12.29	15	20399	1112	50583598
Completed suicide	36.44	12.29	5	20409	131884	50452826
Umbilical erythema	36.14	12.29	8	20406	72	50584638
Death	35.14	12.29	48	20366	325331	50259379
Vertigo positional	34.82	12.29	18	20396	2493	50582217
Abortion spontaneous	34.37	12.29	61	20353	41711	50542999
Drug intolerance	33.80	12.29	176	20238	218928	50365782
Purpura senile	32.58	12.29	11	20403	518	50584192
Death neonatal	32.19	12.29	9	20405	223	50584487
Caesarean section	31.30	12.29	35	20379	15604	50569106
Spondylitis	30.09	12.29	17	20397	2808	50581902
Bronchial obstruction	29.36	12.29	13	20401	1277	50583433
Tarsal tunnel syndrome	28.50	12.29	10	20404	529	50584181
Pain	28.24	12.29	129	20285	578774	50005936
Premature baby	26.82	12.29	35	20379	18302	50566408
Mass excision	26.51	12.29	8	20406	261	50584449
Drug tolerance decreased	26.50	12.29	25	20389	9135	50575575
Stevens-Johnson syndrome	26.49	12.29	38	20376	21714	50562996
Serum sickness-like reaction	25.91	12.29	9	20405	462	50584248
Fall	25.74	12.29	61	20353	334871	50249839
Wound infection	25.71	12.29	28	20386	12120	50572590
Lip swelling	25.54	12.29	40	20374	24696	50560014
Therapeutic product effect incomplete	24.56	12.29	87	20327	91428	50493282
Oligohydramnios	23.29	12.29	19	20395	5731	50578979
Breast cancer stage III	22.85	12.29	15	20399	3241	50581469
Infection	22.67	12.29	133	20281	172821	50411889
Premature rupture of membranes	22.58	12.29	17	20397	4563	50580147
Resorption bone increased	22.41	12.29	10	20404	1001	50583709
Spinal fusion surgery	22.34	12.29	16	20398	3979	50580731
Adjustment disorder with depressed mood	22.31	12.29	14	20400	2800	50581910
Abdominal pain upper	21.85	12.29	124	20290	159185	50425525
Drug ineffective	20.86	12.29	221	20193	819112	49765598
Vestibular disorder	20.24	12.29	10	20404	1259	50583451
Mucous stools	19.47	12.29	13	20401	2889	50581821
Ergot poisoning	19.09	12.29	5	20409	96	50584614
Pharyngeal oedema	19.05	12.29	25	20389	13140	50571570
Maternal drugs affecting foetus	18.94	12.29	16	20398	5061	50579649
Urticaria	18.53	12.29	102	20312	129459	50455251
Corneal neovascularisation	18.49	12.29	5	20409	109	50584601
Corneal perforation	18.28	12.29	7	20407	475	50584235
Acute generalised exanthematous pustulosis	17.88	12.29	20	20394	8918	50575792
Stenotrophomonas infection	17.66	12.29	10	20404	1659	50583051
Nasopharyngitis	17.44	12.29	32	20382	192895	50391815
Alopecia	16.97	12.29	47	20367	245000	50339710
Infantile haemangioma	16.32	12.29	4	20410	58	50584652
Starvation ketoacidosis	15.90	12.29	4	20410	65	50584645
Febrile neutropenia	15.71	12.29	10	20404	97657	50487053
Anal candidiasis	15.63	12.29	3	20411	12	50584698
Type 2 diabetes mellitus	15.21	12.29	39	20375	34336	50550374
Cardiac arrest neonatal	14.39	12.29	4	20410	97	50584613
Hypersensitivity	14.28	12.29	141	20273	215020	50369690
Prescribed overdose	14.23	12.29	23	20391	14577	50570133
Stomatitis	14.19	12.29	12	20402	101332	50483378
Neutropenia	13.85	12.29	24	20390	147941	50436769
Dysphoria	13.75	12.29	13	20401	4761	50579949
Product packaging issue	13.60	12.29	7	20407	960	50583750
Toxicity to various agents	13.10	12.29	43	20371	212456	50372254
Stillbirth	13.09	12.29	14	20400	5938	50578772
Ill-defined disorder	13.07	12.29	3	20411	54651	50530059
Anaemia	13.01	12.29	55	20359	252401	50332309
Pseudomembranous colitis	12.99	12.29	10	20404	2775	50581935
Premature delivery	12.78	12.29	29	20385	23634	50561076
Blepharitis	12.76	12.29	9	20405	2186	50582524
Renal impairment neonatal	12.62	12.29	3	20411	38	50584672
Abdominal pain	12.52	12.29	148	20266	236080	50348630
Haemoglobin decreased	12.50	12.29	20	20394	127196	50457514
Fatigue	12.41	12.29	206	20208	707395	49877315

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	488.24	15.30	280	8194	68126	29497927
Hyphaema	74.49	15.30	19	8455	469	29565584
Toxic epidermal necrolysis	68.48	15.30	50	8424	18103	29547950
Product packaging issue	62.84	15.30	17	8457	530	29565523
Drug interaction	61.49	15.30	158	8316	197227	29368826
Premature baby	44.46	15.30	38	8436	17242	29548811
Dystonia	44.06	15.30	30	8444	9719	29556334
Stupor	39.16	15.30	18	8456	2726	29563327
Rhabdomyolysis	35.52	15.30	63	8411	60745	29505308
Obstruction gastric	34.75	15.30	12	8462	858	29565195
Acute generalised exanthematous pustulosis	34.69	15.30	21	8453	5562	29560491
Coagulation time prolonged	34.47	15.30	13	8461	1197	29564856
Intraocular pressure increased	32.32	15.30	19	8455	4770	29561283
Foetal death	31.26	15.30	8	8466	200	29565853
Eye pain	30.85	15.30	26	8448	11569	29554484
Brain oedema	29.66	15.30	26	8448	12194	29553859
Deafness bilateral	29.52	15.30	11	8463	980	29565073
SAPHO syndrome	28.86	15.30	6	8468	57	29565996
Pyloric stenosis	28.62	15.30	10	8464	740	29565313
Product dispensing error	27.49	15.30	18	8456	5462	29560591
Foetal arrhythmia	25.86	15.30	6	8468	98	29565955
Caesarean section	25.53	15.30	12	8462	1911	29564142
Oligohydramnios	23.59	15.30	7	8467	306	29565747
Oculogyric crisis	22.84	15.30	10	8464	1351	29564702
Onychophagia	22.69	15.30	5	8469	64	29565989
Maternal drugs affecting foetus	22.54	15.30	14	8460	3879	29562174
Low birth weight baby	22.22	15.30	17	8457	6591	29559462
Learning disorder	22.13	15.30	9	8465	1013	29565040
Febrile neutropenia	22.09	15.30	3	8471	112237	29453816
Ototoxicity	21.50	15.30	10	8464	1555	29564498
Tricuspid valve disease	21.48	15.30	6	8468	211	29565842
Respiratory acidosis	21.18	15.30	14	8460	4314	29561739
Sepsis neonatal	20.67	15.30	6	8468	243	29565810
Myasthenia gravis crisis	20.49	15.30	7	8467	484	29565569
Vasculitic rash	20.08	15.30	8	8466	853	29565200
Torsade de pointes	19.94	15.30	16	8458	6645	29559408
Pathogen resistance	19.16	15.30	17	8457	8099	29557954
Swelling face	18.72	15.30	26	8448	20324	29545729
Hepatic necrosis	18.66	15.30	12	8462	3530	29562523
Accidental exposure to product	18.66	15.30	19	8455	10734	29555319
Ischaemic hepatitis	18.54	15.30	9	8465	1539	29564514
Potentiating drug interaction	18.50	15.30	13	8461	4425	29561628
Myoglobinuria	17.84	15.30	7	8467	717	29565336
Hepatic failure	17.55	15.30	32	8442	31480	29534573
Measles	17.53	15.30	5	8469	190	29565863
Cardio-respiratory arrest neonatal	17.32	15.30	3	8471	9	29566044
Neonatal disorder	17.14	15.30	7	8467	796	29565257
Stevens-Johnson syndrome	16.58	15.30	22	8452	16475	29549578
Exposure during pregnancy	16.48	15.30	16	8458	8538	29557515
Brain herniation	15.98	15.30	11	8463	3622	29562431
Pupillary disorder	15.92	15.30	5	8469	265	29565788
Megacolon	15.31	15.30	8	8466	1597	29564456

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	3374.10	12.14	1652	21618	236163	64239299
International normalised ratio fluctuation	190.94	12.14	62	23208	2899	64472563
Bloody discharge	128.99	12.14	39	23231	1438	64474024
Drug interaction	100.83	12.14	323	22947	361760	64113702
Lyme disease	98.87	12.14	36	23234	2379	64473083
Product packaging issue	77.59	12.14	24	23246	956	64474506
Seronegative arthritis	69.96	12.14	29	23241	2714	64472748
Hyphaema	64.60	12.14	19	23251	636	64474826
Necrosis ischaemic	61.01	12.14	20	23250	963	64474499
Toxic epidermal necrolysis	59.16	12.14	70	23200	37096	64438366
Beta haemolytic streptococcal infection	51.62	12.14	21	23249	1873	64473589
Dislocation of vertebra	50.54	12.14	24	23246	3100	64472362
Ototoxicity	50.52	12.14	23	23247	2700	64472762
Pneumonia streptococcal	50.24	12.14	22	23248	2356	64473106
Anaphylactic reaction	47.14	12.14	87	23183	68577	64406885
Wheezing	45.48	12.14	94	23176	80485	64394977
Stevens-Johnson syndrome	42.55	12.14	57	23213	34192	64441270
Exposure during pregnancy	40.80	12.14	88	23182	77587	64397875
Acute generalised exanthematous pustulosis	37.70	12.14	35	23235	14023	64461439
Pneumococcal infection	36.46	12.14	13	23257	808	64474654
Febrile neutropenia	35.01	12.14	12	23258	187645	64287817
Drug intolerance	34.67	12.14	147	23123	187845	64287617
Drug abuse	33.88	12.14	4	23266	132370	64343092
Stupor	33.41	12.14	23	23247	6012	64469450
Completed suicide	33.08	12.14	20	23250	224394	64251068
Drug tolerance decreased	32.58	12.14	24	23246	6974	64468488
Death	32.11	12.14	80	23190	482625	63992837
Caesarean section	32.05	12.14	29	23241	11245	64464217
Vertigo positional	31.39	12.14	17	23253	2894	64472568
Rash	30.96	12.14	276	22994	458273	64017189
Maternal exposure during pregnancy	30.71	12.14	90	23180	95794	64379668
Tarsal tunnel syndrome	30.24	12.14	10	23260	495	64474967
Purpura senile	30.12	12.14	10	23260	501	64474961
Infection	28.41	12.14	137	23133	184743	64290719
Coagulation time prolonged	27.31	12.14	14	23256	2132	64473330
Intraocular pressure increased	26.89	12.14	23	23247	8279	64467183
Lip swelling	26.53	12.14	44	23226	31863	64443599
Torsade de pointes	26.47	12.14	32	23238	17331	64458131
Deafness bilateral	26.10	12.14	13	23257	1863	64473599
Breast cancer stage III	25.97	12.14	15	23255	2890	64472572
Learning disorder	25.60	12.14	9	23261	537	64474925
Serum sickness-like reaction	25.53	12.14	9	23261	541	64474921
Adjustment disorder with depressed mood	25.52	12.14	14	23256	2443	64473019
Respiratory acidosis	25.39	12.14	24	23246	9831	64465631
Oligohydramnios	24.96	12.14	15	23255	3109	64472353
Therapeutic product effect incomplete	23.99	12.14	87	23183	103395	64372067
Bronchial obstruction	23.22	12.14	13	23257	2361	64473101
Spinal fusion surgery	22.81	12.14	15	23255	3636	64471826
Ergot poisoning	22.63	12.14	6	23264	136	64475326
Spondylitis	22.56	12.14	14	23256	3072	64472390
Premature rupture of membranes	22.47	12.14	15	23255	3729	64471733
Oculogyric crisis	22.41	12.14	13	23257	2525	64472937
Product dispensing error	22.37	12.14	24	23246	11426	64464036
Mass excision	22.36	12.14	7	23263	290	64475172
Corneal neovascularisation	22.27	12.14	6	23264	145	64475317
SAPHO syndrome	22.15	12.14	6	23264	148	64475314
Resorption bone increased	22.09	12.14	10	23260	1158	64474304
Wound infection	22.02	12.14	27	23243	14837	64460625
Anaemia	21.28	12.14	68	23202	378612	64096850
Pharyngeal oedema	21.07	12.14	27	23243	15504	64459958
Fall	20.64	12.14	79	23191	416747	64058715
Malignant neoplasm progression	19.73	12.14	8	23262	112863	64362599
Eye pain	19.14	12.14	38	23232	31587	64443875
Haemoglobin decreased	18.53	12.14	26	23244	195037	64280425
Dystonia	18.42	12.14	28	23242	18837	64456625
Vomiting	18.08	12.14	289	22981	550828	63924634
Asthenia	17.61	12.14	87	23183	427957	64047505
Swelling face	17.49	12.14	54	23216	59112	64416350
Tricuspid valve disease	16.63	12.14	6	23264	386	64475076
Neutropenia	16.46	12.14	39	23231	239585	64235877
Rhabdomyolysis	16.32	12.14	71	23199	91655	64383807
Vestibular disorder	15.75	12.14	10	23260	2283	64473179
Abdominal pain upper	15.38	12.14	112	23158	174918	64300544
Ulcerative keratitis	15.28	12.14	11	23259	3086	64472376
Anal candidiasis	15.25	12.14	3	23267	16	64475446
Type 2 diabetes mellitus	15.02	12.14	36	23234	33984	64441478
Myasthenia gravis crisis	14.94	12.14	7	23263	877	64474585
Potentiating drug interaction	14.54	12.14	16	23254	7836	64467626
Live birth	14.45	12.14	19	23251	11185	64464277
Pathogen resistance	14.25	12.14	20	23250	12523	64462939
Starvation ketoacidosis	14.18	12.14	4	23266	115	64475347
Dermatitis allergic	14.15	12.14	22	23248	15087	64460375
Myoglobinuria	14.12	12.14	7	23263	993	64474469
Urticaria	13.95	12.14	96	23174	147221	64328241
Brain oedema	13.94	12.14	27	23243	22048	64453414
Grip strength decreased	13.78	12.14	19	23251	11705	64463757
Walking aid user	13.76	12.14	14	23256	6267	64469195
Hypotension	13.69	12.14	81	23189	380893	64094569
Cardiac arrest neonatal	13.60	12.14	3	23267	30	64475432
Maternal drugs affecting foetus	13.52	12.14	8	23262	1612	64473850
Platelet count decreased	13.44	12.14	25	23245	167686	64307776
Corneal perforation	13.39	12.14	6	23264	678	64474784
Premature delivery	13.31	12.14	24	23246	18565	64456897
Amniotic cavity infection	12.68	12.14	6	23264	768	64474694
Abortion spontaneous	12.64	12.14	28	23242	25115	64450347
Nasopharyngitis	12.61	12.14	33	23237	196040	64279422
Clostridium colitis	12.53	12.14	9	23261	2516	64472946
Pupillary disorder	12.26	12.14	5	23265	449	64475013
Drug resistance	12.25	12.14	34	23236	35068	64440394
Abdominal rigidity	12.21	12.14	9	23261	2618	64472844
Documented hypersensitivity to administered product	12.16	12.14	6	23264	842	64474620

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D10AF02	DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Antiinfectives for treatment of acne
ATC	D10AF52	DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Antiinfectives for treatment of acne
ATC	J01FA01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS Macrolides
ATC	S01AA17	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics
FDA CS	M0028311	Macrolides
FDA PE	N0000009982	Decreased Sebaceous Gland Activity
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011500	Protein Synthesis Inhibitors
FDA EPC	N0000175877	Macrolide
FDA EPC	N0000175935	Macrolide Antimicrobial

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Listeriosis	indication	4241002	DOID:11573
Gonorrhea	indication	15628003	DOID:7551
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Pertussis	indication	27836007
Acute gonococcal urethritis	indication	29864006
Neonatal conjunctivitis	indication	34298002	DOID:9699
Gonorrhea of rectum	indication	42746002
Pneumonia due to Mycoplasma pneumoniae	indication	46970008
Bacterial pneumonia	indication	53084003	DOID:874
Acute gonococcal endometritis	indication	65295003	DOID:7527
Acute bacterial sinusitis	indication	75498004
Syphilis	indication	76272004
Pneumococcal pharyngitis	indication	76651006
Nongonococcal urethritis	indication	84619001
Acne vulgaris	indication	88616000
Urethritis due to Chlamydia trachomatis	indication	179101003
Chlamydial conjunctivitis	indication	231861005	DOID:13800
Pneumococcal pneumonia	indication	233607000
Chlamydial pneumonia	indication	233609002
Neonatal pneumonia	indication	233619008
Erythrasma	indication	238418005	DOID:4131
Streptococcus pyogenes infection	indication	302809008
Infective otitis media	indication	312218008
Diphtheria	indication	397428000
Infection due to Staphylococcus aureus	indication	406602003
Recurrent Persistent Urethritis	indication
Superficial Ocular Infection	indication
Preoperative Bowel Preparation	indication
Prevention of Bacterial Endocarditis	indication
Chlamydia Cervicitis	indication
Rectal Chlamydia Trachomatis Infection	indication
Prevention of Neonatal Ophthalmia	indication
Pneumococcal Acute Otitis Media	indication
Legionnaires' Disease	indication
Rheumatic Fever Prevention	indication
Haemophilus Influenzae Acute Otitis Media	indication
Trachoma	off-label use	2576002	DOID:11265
Inhalational anthrax	off-label use	11389007
Actinomycotic infection	off-label use	11817007	DOID:8478
Enteric campylobacteriosis	off-label use	18081009
Lyme disease	off-label use	23502006	DOID:11729
Granuloma inguinale	off-label use	28867007	DOID:9113
Sinusitis	off-label use	36971009
Erysipelas	off-label use	44653001	DOID:11330
Blepharoconjunctivitis	off-label use	68659002	DOID:2456
Cutaneous anthrax	off-label use	84980006	DOID:7426
Ecthyma	off-label use	85791004
Gastrointestinal anthrax	off-label use	111798006	DOID:13386
Bacterial conjunctivitis	off-label use	128350005	DOID:9700
Bacterial infection of skin	off-label use	128936008
Lymphogranuloma venereum	off-label use	186946009	DOID:13819
Gastroesophageal reflux disease	off-label use	235595009	DOID:8534
Gastroparesis	off-label use	235675006
Chancroid	off-label use	266143009	DOID:13778
Meibomianitis	off-label use	309779001
Infective blepharitis	off-label use	312219000
Bacterial keratitis	off-label use	314557000
Erysipeloid	off-label use	400105005
Anthrax	off-label use	409498004	DOID:7427
Relapsing fever	off-label use	420079008	DOID:13034
Gastroscopy Adjunct	off-label use
Listeria Monocytogenes Septicemia	off-label use
Ureaplasma Pneumonia	off-label use
Torsades de pointes	contraindication	31722008
Third trimester pregnancy	contraindication	41587001
Megaloblastic anemia due to folate deficiency	contraindication	85649008	DOID:14026
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Cholestatic hepatitis	contraindication	95556007
Anemia due to enzyme deficiency	contraindication	111577008
Prolonged QT interval	contraindication	111975006
Hearing disorder	contraindication	128540005
Liver function tests abnormal	contraindication	166603001
Disease of blood AND/OR blood-forming organ	contraindication	191124002	DOID:74
Disease of liver	contraindication	235856003	DOID:409
Pseudomembranous enterocolitis	contraindication	397683000
Erythroderma	contraindication	399992009
Porphyria	contraindication	418470004
Congenital long QT syndrome	contraindication	442917000
Inflammatory dermatosis	contraindication	703938007

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Bacterial pneumonia	Indication
Cats	Upper respiratory infections	Indication
Cats	Secondary infections associated with panleukopenia	Indication
Cats	Bacterial wound infections caused by Staphylococcus species	Indication
Cats	Bacterial wound infections caused by Streptococcus species	Indication
Cattle	Bovine respiratory disease (BRD) associated with Pasturella multiocida	Indication
Cattle	Mastitis caused by Staphylococcus aureus	Indication
Cattle	Mastitis caused by Streptococcus dysgalactiae	Indication
Cattle	Mastitis caused by Streptococcus dysgalactiae	Indication
Cattle	Mastitis caused by Streptococcus uberis	Indication
Chickens	Prevention and reduction of lesions and in lowering severity of chronic respiratory disease	Indication
Chickens	Prevention of infectious coryza	Indication
Chickens	Prevention of chronic respiratory disease during periods of stress	Indication
Chickens	Chronic respiratory disease caused by Mycoplasma gallisepticum	Indication
Chickens	Infectious coryza caused by Hemophilus gallinarum	Indication
Dogs	Bacterial pneumonia	Indication
Dogs	upper respiratory infections	Indication
Dogs	Endometritis and metritis	Indication
Dogs	Bacterial wound infections caused by Staphylococcus species	Indication
Dogs	Bacterial wound infections caused by Streptococcus species	Indication
Dogs	Bacterial wound infections caused by Corynebacterium species	Indication
Turkeys	Chronic respiratory disease during periods of stress	Indication
Turkeys	Prevention and reduction of lesions and in lowering severity of chronic respiratory disease	Indication
Turkeys	Control of blue comb (nonspecific infectious enteritis)	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Gallimycin-100P	Bimeda Animal Health Limited	1
Erythro - 100, 200, Gallimycin-100	Bimeda Animal Health Limited	1
Gallimycin PFC	Bimeda Animal Health Limited	1
Erythro-36 Dry, Gallimycin-36 Dry	Bimeda Animal Health Limited	1
Gallimycin-36 Sterile	Bimeda Animal Health Limited	1
Erythromast 36	Zoetis Inc.	1
Erythro-100 Injection	Bimeda Animal Health Limited	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.65	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
250MG	ERYTHROMYCIN	TORRENT	A211975	July 26, 2021	RX	TABLET, DELAYED RELEASE	ORAL	April 2, 2022	COMPETITIVE GENERIC THERAPY
500MG	ERYTHROMYCIN	TORRENT	A211975	July 26, 2021	RX	TABLET, DELAYED RELEASE	ORAL	April 2, 2022	COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN	IC50	7.41	CHEMBL
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN	IC50	4.82	WOMBAT-PK
Bile salt export pump	Transporter	O95342	ABCBB_HUMAN	IC50	5.39	CHEMBL
Motilin receptor	GPCR	O43193	MTLR_HUMAN	Ki	4.43	CHEMBL
Cytochrome P450 1B1	Enzyme	Q16678	CP1B1_HUMAN	IC50	4.40	CHEMBL

External reference:

ID	Source
4017594	VUID
N0000145975	NUI
D00140	KEGG_DRUG
4017591	VANDF
4017594	VANDF
4017595	VANDF
4017596	VANDF
C0014806	UMLSCUI
CHEBI:42355	CHEBI
ERY	PDB_CHEM_ID
CHEMBL2110577	ChEMBL_ID
CHEMBL532	ChEMBL_ID
CHEMBL1200506	ChEMBL_ID
CHEMBL3545060	ChEMBL_ID
CHEMBL1200510	ChEMBL_ID
D004917	MESH_DESCRIPTOR_UI
DB00199	DRUGBANK_ID
C010948	MESH_SUPPLEMENTAL_RECORD_UI
C011462	MESH_SUPPLEMENTAL_RECORD_UI
1456	IUPHAR_LIGAND_ID
C025000	MESH_SUPPLEMENTAL_RECORD_UI
39	INN_ID
4501-00-2	SECONDARY_CAS_RN
7704-67-8	SECONDARY_CAS_RN
63937KV33D	UNII
12560	PUBCHEM_CID
24346	RXNORM
33316	MMSL
3627	MMSL
4675	MMSL
4678	MMSL
4679	MMSL
4680	MMSL
4769	MMSL
4799	MMSL
72164	MMSL
d00046	MMSL
002755	NDDF
002758	NDDF
002759	NDDF
002760	NDDF
30427009	SNOMEDCT_US
372694001	SNOMEDCT_US
39152007	SNOMEDCT_US
698006	SNOMEDCT_US
83981000	SNOMEDCT_US
96032005	SNOMEDCT_US
96033000	SNOMEDCT_US
23067-13-2	SECONDARY_CAS_RN
3847-29-8	SECONDARY_CAS_RN
643-22-1	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5571	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5572	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
ERYGEL	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8075	GEL	20 mg	TOPICAL	NDA	18 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8212	GEL	20 mg	TOPICAL	NDA authorized generic	18 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0404-7191	OINTMENT	5 mg	OPHTHALMIC	ANDA	18 sections
Erythrocin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-6476	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	13 sections
Erythrocin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-6482	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	NDA	13 sections
erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0574-4024	OINTMENT	5 mg	OPHTHALMIC	ANDA	18 sections
Erythrocin Stearate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-594	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Erythrocin Stearate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-595	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	13668-586	TABLET, DELAYED RELEASE	250 mg	ORAL	ANDA	25 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	13668-588	TABLET, DELAYED RELEASE	500 mg	ORAL	ANDA	25 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-606	TABLET, COATED	250 mg	ORAL	ANDA	14 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-607	TABLET, COATED	500 mg	ORAL	ANDA	14 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13985-605	OINTMENT	5 mg	OPHTHALMIC	ANDA	18 sections
Erythromycin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	14789-116	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	24 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-088	CAPSULE, DELAYED RELEASE	250 mg	ORAL	ANDA	22 sections
ERY-TAB	HUMAN PRESCRIPTION DRUG LABEL	1	16590-089	TABLET, DELAYED RELEASE	333 mg	ORAL	ANDA	27 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-090	OINTMENT	5 mg	OPHTHALMIC	ANDA	9 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-091	TABLET, FILM COATED	250 mg	ORAL	ANDA	17 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	17478-070	OINTMENT	5 mg	OPHTHALMIC	ANDA	19 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-173	OINTMENT	5 mg	OPHTHALMIC	ANDA	15 sections
ERYTHROMYCIN Base Filmtab	HUMAN PRESCRIPTION DRUG LABEL	1	21695-387	TABLET, FILM COATED	250 mg	ORAL	ANDA	24 sections
ERYTHROMYCIN Base Filmtab	HUMAN PRESCRIPTION DRUG LABEL	1	21695-389	TABLET, FILM COATED	500 mg	ORAL	ANDA	24 sections
ERY-TAB	HUMAN PRESCRIPTION DRUG LABEL	1	21695-457	TABLET, DELAYED RELEASE	333 mg	ORAL	ANDA	23 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	24208-910	OINTMENT	5 mg	OPHTHALMIC	ANDA	8 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	24338-102	TABLET, FILM COATED	250 mg	ORAL	ANDA	27 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	24338-104	TABLET, FILM COATED	500 mg	ORAL	ANDA	27 sections
Erythrocin Stearate	HUMAN PRESCRIPTION DRUG LABEL	1	24338-106	TABLET, FILM COATED	250 mg	ORAL	ANDA	27 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	24338-120	CAPSULE, DELAYED RELEASE	250 mg	ORAL	ANDA	27 sections